Pacific GeneTech

Pacific GeneTech is a biotechnology firm focused on the development and commercialization of advanced vaccines for food safety and animal health, particularly livestock. Partially funded by the US Government, the company was established to commercialize the Aegis platform developed by a consortium of leading US universities.

The Aegis vaccine platform is a proprietary technology that combines cross-protective antigens and immunopotentiators in vectors to provide broad protection against multiple strains and species of pathogens. This platform has been expanded beyond its initial applications in poultry to include vaccines for pigs, ruminants (cows and sheep), and companion animals. The company’s other vaccines include the cross-protective Salmonella vaccine (CPH001), cross-protective swine enteric vaccinee (CPH002), and parasite vaccine for Eimeria in poultry (TMH001).

Key customers and partnerships

The company partners with academic institutions and other industry players to advance its R&D efforts.

Funding and financials

In August 2022, the company raised USD 10 million in equity financing backed by Whist Subholdings, PT Medion, FHB Ventures, the Arkansas Development Finance Authority (ADFA), and Simmons Foods. The funds were earmarked to accelerate the development of its Aegis platform.